Sign in
CompletedNo phase

Discontinuation of Hypnotics in Older Veterans

Key facts

Who runs it
VA Office of Research and Development
Where
West Los Angeles, United StatesSee the site
Trial code
Status
Completed
People taking part
132 people enrolled
Started
10 Dec 2018
Ended
27 Nov 2023
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • CBTI plus taper method A
  • CBTI plus taper method B
Record updated
14 November 2024

Who can take part

Age
55 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Age >= 55 years
  • Use of lorazepam, alprazolam, temazepam, clonazepam, and/or zolpidem for current or prior insomnia symptoms 2 or more nights per week for at least 3 months
  • Current or prior insomnia symptoms
  • Available to attend weekly in-person or video sessions over 9 weeks

Who cannot take part

  • Unable to keep study medications in secure location
  • Evidence of prescription fraud (e.g., multiple prescriptions for same drug filled at VA and non-VA pharmacies, diversion); Discontinuation of hypnotic not appropriate:
  • Medically/psychiatrically unstable (e.g., recent major hospitalization or planned major surgery during the study; psychosis, suicidal, active alcohol/substance abuse based on history and medical records)
  • Seizure disorder
  • High risk of complicated withdrawal; benzodiazepine intoxication or current or past symptoms of complicated benzodiazepine/alcohol withdrawal (e.g., seizure, delirium at baseline)
  • Study-targeted hypnotic used to treat another clinical condition (e.g., Rapid Eye Movement sleep behavior disorder)
  • Presence of bipolar disorder
  • Cognitive impairment (e.g., Mini-Mental State Examination < 24)
  • Sleep/wake difficulty is better explained by another sleep disorder such as restless legs syndrome, narcolepsy, insufficient sleep syndrome, or circadian rhythm sleep-wake disorders
  • High risk for complications in outpatient hypnotic discontinuation program:
  • Supratherapeutic/high baseline hypnotic dose (> diazepam-equivalent of 8 mg/night). Note that for individuals on > 1 of the targeted hypnotics, total baseline dose in diazepam-equivalents will be calculated \& if > 8 mg/night, individual will be excluded
  • Polydrug use (e.g., chronic high dose opioids)
  • Not willing to begin hypnotic discontinuation program; Poor candidate for CBTI:
  • Untreated sleep-disordered breathing defined as:; Apnea-hypopnea index (AHI) > 30 AHI between 15 and 30 and daytime sleepiness (Epworth Sleepiness Scale > 10)
  • Unstable housing situation

Where in United States

  • VA Greater Los Angeles Healthcare System, West Los Angeles, CAWest Los Angeles, United States

About the trial

What the trial wants to find out

Sleeping medications, called hypnotics, are often prescribed for insomnia. About one-quarter of Veterans use hypnotics (or bedtime alcohol). Older patients who use hypnotics fall more often and have worse memory than those who do not use them. Stopping hypnotics often reverses these problems. The Department of Veterans Affairs (VA) is trying to reduce hypnotic use among older adults. Currently, there are two main treatments to help patients stop using hypnotics. The first treatment involves a slow decrease in the daily dose until the hypnotic is ultimately discontinued. For safety, the process of decreasing the daily dose is usually supervised by a physician. The second is a treatment for insomnia called cognitive behavioral therapy for insomnia (CBTI).

Read full original descriptionShow less

This study will compare a novel hypnotic tapering method to the usual tapering method offered to older Veterans. The purpose of the study is to determine if the novel tapering method is more effective than the usual tapering method, both in terms of hypnotic discontinuation and improvement in insomnia severity.

Participants will be recruited from among Veterans 55 years and older who receive care from one VA Healthcare System. Following a baseline assessment, participants will be randomly assigned to one of the two 8-week treatment groups (66 participants per group). Each treatment group will receive CBTI, however, one group will receive the novel tapering program and the other group the usual tapering program. Follow-up assessments will be conducted at post-treatment and at 6-months after completion of the treatment.

If the novel tapering program is effective, it will represent a treatment option that can be offered to older Veterans who want to discontinue hypnotics. This tapering program could help VA healthcare providers adhere to clinical guidelines that recommend benzodiazepine discontinuation among older adults. A reduction in chronic hypnotic use may in turn reduce the risk of falls and hip fractures, which ultimately may improve the health and quality of life of older Veterans who receive healthcare at the VA.

The 2 groups in the trial

  • CBTI plus Taper method ATreatment being tested

    Participants in this arm will receive Cognitive Behavioral Therapy for Insomnia (CBTI) plus the novel hypnotic tapering method.

  • CBTI plus Taper method BExisting treatment, for comparison

    Participants in this arm will receive Cognitive Behavioral Therapy for Insomnia (CBTI) plus the usual tapering method used by the VA.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Efficacy of Masked Tapering on Discontinuation of Hypnotics in Older Veterans
Record updated
14 November 2024